Impact News +++ California Resources reports mixed Q2 results; reaffirms FY26 outlook (SeekingAlpha) +++ CALIFORNIA RESOURCES Aktie -3,81%

AXSOME Aktie

>AXSOME Aktienkurs

185.2 EUR +0.7% (TradegateBSX)

Ask: 190.15 EUR / 20 Stück

Bid: 185.4 EUR / 20 Stück

Tagesumsatz: 765 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

AXSOME Aktie über LYNX handeln

Intraday

1 Jahr

>AXSOME Performance

1 Woche: -3,2%

1 Monat: -16,3%

3 Monate: -1,6%

6 Monate: +20,8%

1 Jahr: +106,8%

laufendes Jahr: +43,7%

>AXSOME Aktie

Profil:

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for central nervous system conditions with limited treatment options. Headquartered in New York City and founded in 2012, the comp..
>Volltext..

Insiderhandel:

>AXSOME Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>AXSOME Peer Group

Gesundheit, Demenz/ Alzheimer- Behandlung, Neurologische Erkrankungen/ Schlaganfälle, Psychische Erkrankungen/ Depressionen/ Schizophrenie

>AXSOME Chart & Kurs - NASDAQ

>AXSOME News

10.08.26 - 13:12	Axsome Therapeutics GAAP EPS of -$0.99 misses by $0.10, revenue of $218.4M misses by $3.38M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.26 - 03:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Axsome Therapeutics im Wert von 9541298 USD (Insiderkauf)
	Tabuteau, Herriot - Vorstand - Tag der Transaktion: 2026-08-05...

08.08.26 - 03:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Axsome Therapeutics im Wert von 997007 USD (Insiderkauf)
	Tabuteau, Herriot - Vorstand - Tag der Transaktion: 2026-08-06...

07.08.26 - 18:00	Axsome Therapeutics Q2 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.26 - 16:33	The Next Billion-Dollar Opportunity in Alzheimer′s Disease Market: 6 Pipeline Therapies to Watch \| DelveInsight (PR Newswire)
	The Alzheimer's disease market dynamics are anticipated to change due to the expected launch of emerging therapies, such as Masupirdinea (Suven Life Sciences), Trontinemabb (Roche), Buntanetap (Annovis bio), Masitinib (AB Science), Remternetug (Eli Lilly), AUVELITY (AXS-05) (Axsome......

03.08.26 - 17:30	Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
	Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

16.07.26 - 19:15	Axsome′s NDA for AXS-12 in Narcolepsy Gets FDA Acceptance (Zacks)
	AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date....

15.07.26 - 14:00	Axsome gains as narcolepsy therapy undergoes FDA review (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.07.26 - 13:03	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy (GlobeNewswire EN)
	FDA sets PDUFA target action date of May 1, 2027...

14.07.26 - 13:03

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 (GlobeNewswire EN)

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2026 on Monday, August 10, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update....

09.07.26 - 10:24	Better Growth Buy: Axsome vs Revolution Medicines (Fool)
	These stocks both scored a win in the first half of the year....

08.07.26 - 19:00	Axsome Begins Phase III Study on Solriamfetol for ADHD in Children (Zacks)
	AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years....

07.07.26 - 13:03	Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) (GlobeNewswire EN)
	The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD...

02.07.26 - 14:36	Is Axsome Therapeutics Stock a Millionaire Maker? Here′s What the Numbers Say. (Fool)
	The stock has soared more than 220% in three years....

02.07.26 - 05:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Axsome Therapeutics im Wert von 11932257 USD (Insiderkauf)
	Tabuteau, Herriot - Vorstand - Tag der Transaktion: 2026-07-01...

26.06.26 - 13:03	Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) (GlobeNewswire EN)
	NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder (ADHD)....

18.06.26 - 13:03	Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer′s & Brain Awareness Month (GlobeNewswire EN)
	NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining patients, caregivers, and advocacy organizations in raising awareness of brain health and the impact of Alzheimer's disease during Alzheimer's & Brain Awareness Month....

15.06.26 - 13:03

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 (GlobeNewswire EN)

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data on AXS-12 and solriamfetol at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 14-17, 2026, in Baltimore, Maryland....

12.06.26 - 07:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Axsome Therapeutics im Wert von 71248 USD (Insiderkauf)
	Jeffs, Roger - Aufsichtsrat - Tag der Transaktion: 2026-06-11...

12.06.26 - 07:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Axsome Therapeutics im Wert von 70407 USD (Insiderkauf)
	Jeffs, Roger - Aufsichtsrat - Tag der Transaktion: 2026-06-10...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Überalterung ist vor allem ein Problem der leitenden Gremien. - Dr. Gerhard Kocher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram